Respiratory

Description

• Allergens are the main cause for most allergic conditions like chronic allergic rhinitis, post-nasal drip and allergic asthma. These allergic manifestations are also accompanied by inflammation. Hence, in such conditions, it is not only important to take care of allergy but inflammation as well.
• Montelukast sodium is an orally active compound that binds with high affinity and selectivity to the CysLT type-1 (CysLT1) receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. It therefore acts as a leukotriene receptor antagonist. Levocetirizine (as Levocetirizine dihydrochloride) is a third-generation, non-sedative antihistamine. Chemically, levocetirizine is the active enantiomer of cetirizine. Levocetirizine works by blocking histamine receptors. It does not prevent the actual release of histamine from mast cells, but prevents its binding to the receptors. This in turn prevents the release of other allergic chemicals and increases blood supply to the area and provides relief from the typical symptoms of allergy.
• Recent studies have demonstrated that allergic rhinitis when treated concomitantly with an antileukotriene (Montelukast) and an antihistamine (Levocetirizine), shows significantly better symptom relief compared with the modest improvement of rhinitis symptoms with each of the treatment alone.

Indications

For the relief and/or prevention of symptoms associated with:

• Intermittent allergic rhinitis and persistent allergic rhinitis
•  Allergic rhinitis associated with asthma.